Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro
Executive Summary
Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.
You may also be interested in...
Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx
Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.
Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx
Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.
Business News, In Brief
Isis banks on milestones from partners, Onyx rakes in higher-than-expected revenues from Kyprolis, Seattle Genetics announces trial delays, and other news from biopharma’s first quarter.